ReviewNature reviews. Immunology2009
Cracking the BAFF code.
Review in Nature reviews. Immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 508 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
508 citing papers in PubMed, 2 syntheses or guidelines pooled it, 880 citations in OpenAlex.
- CAR-based cellular therapy for refractory systemic lupus erythematosus: an overlap-controlled systematic review.Frontiers in immunology · 2026Pooled it
- Efficacy and safety of novel biologics in the treatment of lupus nephritis based on registered clinical trials: a systematic review and network meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Expansion of inflammatory monocytes in periphery and infiltrated into thyroid tissue in Graves' disease.Scientific reports · 2021Trial
- Targeting the B-Cell Activating Factor and a Proliferation-Inducing Ligand Pathway in IgAN: From Disease Pathogenesis to Clinical Trial Evidence.Kidney international reports · 2026Review
- Targeting B-Cell-Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia.American journal of hematology · 2026Review
- Postbiotics enhance immune competence in black rockfish (Sebastes schlegelii): linking innate immunity, apoptosis, and resistance to bacterial infection.Journal of animal science and biotechnology · 2026Article
- Rheumatoid factor production is genetically and molecularly distinct from rheumatoid arthritis.The Journal of clinical investigation · 2026Article
- B-cell targeting strategies for the treatment of multiple sclerosis: from non-cellular therapies to CAR-engineered cell therapies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Managing Sjögren's Disease in Pediatric Patients.Paediatric drugs · 2026Review
- Real-world effectiveness of telitacicept in ebv-seropositive patients with systemic lupus erythematosus.Clinical rheumatology · 2026Article
- Efficacy and safety of telitacicept for rituximab-refractory membranous nephropathy.International urology and nephrology · 2026Article
- Baicalein Attenuates Eosinophilic Rhinosinusitis by Suppressing ALOX15-Mediated M2 Macrophage Function.International journal of molecular sciences · 2026Article
- Humoral immunity in cancer.Signal transduction and targeted therapy · 2026Review
- CAR T cell therapy beyond cancer: current status, challenges and future prospects.Signal transduction and targeted therapy · 2026Review
- Article
- Vaccine Responses in Early Age.Vaccines · 2026Review
- Decoding Lupus Diagnosis, Pathogenesis and Therapy: From Systemic Autoimmunity to Renal Damage.Diagnostics (Basel, Switzerland) · 2026Review
- Stage-resolved mapping of RP105 (CD180)-negative B cells reveals residual plasmablast-lineage skewing in SLE: a cross-sectional study.Lupus science & medicine · 2026Article
- Staphylococcus aureus Pyogenic Spondylodiscitis in a Patient With Rheumatoid Arthritis Receiving Rituximab.Cureus · 2026Article
- Inflammatory Biomarkers Are Associated with Pain and Functional Impairment in Knee Osteoarthritis Patients: A Cross-Sectional Pilot Study.Journal of clinical medicine · 2026Article
448 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumour necrosis factor (TNF) family members B cell activating factor (BAFF) and APRIL (a proliferation-inducing ligand) are crucial survival factors for peripheral B cells. An excess of BAFF leads to the development of autoimmune disorders in animal models, and high levels of BAFF have been detected in the serum of patients with various autoimmune conditions. In this Review, we consider the possibility that in mice autoimmunity induced by BAFF is linked to T cell-independent B cell activation rather than to a severe breakdown of B cell tolerance. We also outline the mechanisms of BAFF signalling, the impact of ligand oligomerization on receptor activation and the progress of BAFF-depleting agents in the clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.